Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 16/20 | 0.56 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.56 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.56 |
| ▸ | PPARD | Q03181 | 4/20 | 0.50 |
| ▸ | PPARA | Q07869 | 3/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30396158 | 1.00 | S1PR1 (0.56) | S1PR1S1PR4S1PR5PPARDPPARA | |
| SCHEMBL22074080 | 0.92 | S1PR1 (0.54) | S1PR1S1PR4S1PR5PPARDPPARA | |
| SCHEMBL30395758 | 0.89 | S1PR1 (0.64) | S1PR1S1PR4S1PR5PPARDPPARA | |
| SCHEMBL24165701 | 0.89 | S1PR1 (0.64) | S1PR1S1PR4S1PR5PPARDPPARA | |
| SCHEMBL26755561 | 0.85 | S1PR1 (0.57) | S1PR1S1PR4S1PR5PPARDPPARA | |
| SCHEMBL22077188 | 0.85 | S1PR1 (0.55) | S1PR1S1PR4S1PR5PPARDPPARA | |
| SCHEMBL26620585 | 0.85 | S1PR1 (0.56) | S1PR1S1PR4S1PR5PPARDPPARA | |
| SCHEMBL22074082 | 0.84 | S1PR1 (0.62) | S1PR1S1PR4S1PR5PPARDPPARA | |
| SCHEMBL24165554 | 0.81 | S1PR1 (0.46) | S1PR1S1PR4S1PR5ADORA3S1PR2 | |
| SCHEMBL24165717 | 0.81 | S1PR1 (0.46) | S1PR1S1PR4S1PR5ADORA3S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357148-A1 | INDOLE DERIVATIVE AND APPLICATION THEREOF | SHANGHAI MEDICILON INC. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357148-A1 | INDOLE DERIVATIVE AND APPLICATION THEREOF | SHANGHAI MEDICILON INC. (CN) | 2023-11-09 | — | — | US | disclosed |
| CN-113880747-B | Indole derivative and application thereof | 上海美迪西生物医药股份有限公司 | 2023-05-26 | — | — | CN | disclosed |
| WO-2022002225-A1 | INDOLE DERIVATIVE AND APPLICATION THEREOF | 上海美迪西生物医药股份有限公司 | 2022-01-06 | — | — | WO | disclosed |
| CN-113880747-A | Indole derivative and application thereof | 上海美迪西生物医药股份有限公司 | 2022-01-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357148-A1 | INDOLE DERIVATIVE AND APPLICATION THEREOF | S1PR1, S1PR3, S1PR5 | S1PR1 1/4885S1PR4 6/4885S1PR5 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.